Get the Stockscreener App
28.07
1.18%
0.3895
Moderna Inc stock is traded at $28.07, with a volume of 4.71M.
It is up +1.18% in the last 24 hours and up +15.49% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$27.68
Open:
$28
24h Volume:
4.71M
Relative Volume:
0.45
Market Cap:
$10.76B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.2153
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+2.70%
1M Performance:
+15.49%
6M Performance:
-34.65%
1Y Performance:
-81.13%
1-Day Range:
$27.70
$28.72
1-Week Range:
$25.82
$29.19
52-Week Range:
$23.15
$150.74
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
28.03 | 10.76B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.64 | 114.65B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.10 | 52.67B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.23 | 39.61B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
580.97 | 35.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
106.87 | 27.80B | 2.97B | -812.83M | -1.24B | -3.3962 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial - Benzinga
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 | MRNA Stock News - GuruFocus
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar
Rhumbline Advisers Has $16.94 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
TB Alternative Assets Ltd. Takes $18.50 Million Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Sees Mixed Options Sentiment with Slight Price Dip | MRNA Stock News - GuruFocus
‘People inside Moderna are afraid’: As anti-vaccine climate intensifies, the company has much to lose - statnews.com
Vaccine actions and policy positions under US Health Secretary Kennedy - Reuters
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's
American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance - Benzinga
GAMMA Investing LLC Acquires 221,529 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Will Test New Covid Shot Against Placebo, RFK Jr. Says - MSN
Funding canceled for bird flu vaccine - KSWT
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Moderna, Pfizer, and BioNTech stocks dip on vaccine panel overhaul By Investing.com - Investing.com Canada
MAHA v. Moderna: The COVID vaccine maker is under attack by RFK Jr.'s department of health - Fast Company
How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks? - MSN
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike - MSN
Moderna Wins Narrower US Approval for New Covid Vaccine - MSN
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your RightsMRNA - ACCESS Newswire
10,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by LVW Advisors LLC - MarketBeat
15,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Alpha Wealth Funds LLC - MarketBeat
DraftKings, Teladoc, Rush Street Interactive, Moderna, and Avis Budget Group Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Moderna Stock A Buy After Winning A Surprise Approval? - Investor's Business Daily
Green Alpha Advisors LLC Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s human/AI revampthe human implications and how to manage them - Diginomica
How Is Moderna’s Stock Performance Compared To Other Biotechnology Stocks? - Barchart.com
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of “Hold” by Brokerages - Defense World
Trump administration cancels Moderna contract to fight bird flu and other viruses - news8000.com
Moderna at Jefferies Conference: Strategic Growth and Challenges - Investing.com
Fed Circ upholds Moderna’s COVID-19 vaccine win against Alnylam - Life Sciences Intellectual Property Review
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
Transcript : Moderna, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 10 - marketscreener.com
Moderna’s HR-IT merger: Trend or exception to the rule? - cio.com
Fed. Circ. Upholds Moderna's IP Win Over COVID Vax - Law360
Alnylam Fails to Revive Patent Infringement Suit Against Moderna - Bloomberg Law News
Strict Standard for Overriding Patent Lexicography in COVID Vaccine Patent Battle - Patently-O
CAFC Affirms Moderna’s Win, Holding Alnylam Narrowly Defined ‘Branched Alkyl’ - IPWatchdog.com
Class Action Filed Against Moderna, Inc. (MRNA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
US appeals court sides with Moderna on COVID patent claims - Reuters
Moderna (MRNA) to Conduct New Trial for Next-Gen COVID Vaccine - GuruFocus
RFK Jr. says Moderna agreed to another clinical trial to support new COVID shot - Seeking Alpha
Down 80%, Should You Buy the Dip on Moderna? - AOL.com
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says - whbl.com
Moderna will test new Covid shot against Placebo, Robert F Kennedy Jr. says - CNBC TV18
Moderna (MRNA) Will Test New Covid Shot Against Placebo, RFK Jr. Says - Bloomberg
CDC official resigns from COVID vaccine committee advisory role, sources say - marketscreener.com
FDA grants limited approval to Moderna’s new mRNA COVID vaccine By Investing.com - Investing.com Canada
Moderna's (MRNA) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
0.66%
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):